SOLV Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 14.91%. Solventum Corp.'s return on equity of 42.2% beat Boston Scientific Corp.'s return on equity of 12.46%.

Solventum Corp. has a consensus price target of $85.64, signalling upside risk potential of 6.43%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than Solventum Corp., analysts believe Boston Scientific Corp. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Solventum Corp. quarterly revenues are $2.1B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Solventum Corp.'s net income of $1.3B is higher than Boston Scientific Corp.'s net income of $755M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.26x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.67x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 15.47%. Solventum Corp.'s return on equity of 42.2% beat Globus Medical, Inc.'s return on equity of 10.08%.

Solventum Corp. has a consensus price target of $85.64, signalling upside risk potential of 6.43%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 11.67%. Given that Globus Medical, Inc. has higher upside potential than Solventum Corp., analysts believe Globus Medical, Inc. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Solventum Corp. quarterly revenues are $2.1B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Solventum Corp.'s net income of $1.3B is higher than Globus Medical, Inc.'s net income of $119M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.26x while Globus Medical, Inc.'s PE ratio is 28.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.67x versus 4.40x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 26.1%. Solventum Corp.'s return on equity of 42.2% beat ResMed, Inc.'s return on equity of 25.6%.

Solventum Corp. has a consensus price target of $85.64, signalling upside risk potential of 6.43%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that ResMed, Inc. has higher upside potential than Solventum Corp., analysts believe ResMed, Inc. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. Solventum Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum Corp. quarterly revenues are $2.1B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Solventum Corp.'s net income of $1.3B is higher than ResMed, Inc.'s net income of $348.5M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.26x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.67x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona, Inc. has a net margin of 60.4% compared to Solventum Corp.'s net margin of -47.35%. Solventum Corp.'s return on equity of 42.2% beat Dentsply Sirona, Inc.'s return on equity of -44.58%.

Solventum Corp. has a consensus price target of $85.64, signalling upside risk potential of 6.43%. On the other hand Dentsply Sirona, Inc. has an analysts' consensus of $12.77 which suggests that it could grow by 10.82%. Given that Dentsply Sirona, Inc. has higher upside potential than Solventum Corp., analysts believe Dentsply Sirona, Inc. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dentsply Sirona, Inc. has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.82100000000001%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona, Inc. offers a yield of 5.56% to investors and pays a quarterly dividend of $0.16 per share. Solventum Corp. pays -- of its earnings as a dividend. Dentsply Sirona, Inc. pays out 13.85% of its earnings as a dividend. Dentsply Sirona, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum Corp. quarterly revenues are $2.1B, which are larger than Dentsply Sirona, Inc. quarterly revenues of $904M. Solventum Corp.'s net income of $1.3B is higher than Dentsply Sirona, Inc.'s net income of -$428M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.26x while Dentsply Sirona, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.67x versus 0.63x for Dentsply Sirona, Inc.. Usually stocks with elevated PS ratios are considered overvalued.